27 Jun 2023 --- As using psychedelic drugs for treating medical conditions gains interest and popularity, the US Food and Drug Administration (FDA) has issued guidance to the industry. The guidance sponsors the development of psychedelic-based treatments and has left a 60-day window for comments on the paper. The guidance includes “classic psychedelics” such as psilocybin and lysergic acid diethylamide (LSD) that act on the brain’s serotonin system, and the empathogen methylenedioxymethamphetamine (MDMA).
